Arbutus Biopharma Corporation is a biopharmaceutical company which is focused on discovering, developing and commercializing a portfolio of drug candidates for chronic hepatitis B infection. The Company's products include TKM-HBV, Cyclophilin Inhibitor-OCB-030, TLR9 Agonist (CYT-003), Capsid Assembly Inhibitors, Surface Antigen Secretion Inhibitors, STING Agonists, cccDNA Formation Inhibitors, cccDNA Epigenetic Modifiers, TKM-PLK1, GI-NET and ACC, HCC, TKM-Ebola, TKM-Ebola-Guinea, TKM-Marburg, TKM-HTG and TKM-ALDH which are in different clinical trial stage. Arbutus Biopharma Corp, formerly known as Tekmira Pharmaceuticals Corporation, is headquartered in Vancouver, BC.
| Revenue (Most Recent Fiscal Year) | $6.17M |
| Net Income (Most Recent Fiscal Year) | $-69.92M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 105.59 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 8.54 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -1195.86% |
| Net Margin (Trailing 12 Months) | -1196.64% |
| Return on Equity (Trailing 12 Months) | -75.51% |
| Return on Assets (Trailing 12 Months) | -55.81% |
| Current Ratio (Most Recent Fiscal Quarter) | 6.01 |
| Quick Ratio (Most Recent Fiscal Quarter) | 6.01 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.04 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $0.51 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.13 |
| Earnings per Share (Most Recent Fiscal Year) | $-0.38 |
| Diluted Earnings per Share (Trailing 12 Months) | $-0.41 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 191.53M |
| Free Float | 152.65M |
| Market Capitalization | $676.09M |
| Average Volume (Last 20 Days) | 0.62M |
| Beta (Past 60 Months) | 1.23 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 20.30% |
| Percentage Held By Institutions (Latest 13F Reports) | 43.79% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |